Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain


<p>Aug 27, 2007 (PRNewswire-Diamyd Medical AB)- Diamyd Medical announced today that NP2, the company’s first drug candidate in its nerve targeting drug delivery system (NTDDS) gene therapy platform, will be the subject of a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration on August 29, 2007…</p>